Skip to main content
. 2024 Nov 17:e244539. Online ahead of print. doi: 10.1001/jamacardio.2024.4539

Figure 1. Potassium Levels During the Study by Treatment .

Figure 1.

The increase in serum potassium was greater in the finerenone group than the placebo group at 1 month (median [IQR] difference, 0.19 [0.17-0.21] mmol/L) and 3 months (median [IQR] difference, 0.23 [0.21-0.25] mmol/L), which persisted for the remainder of trial follow-up.